Over the latest trailing 12-month period, price cagr is +100.24%. The comparable SPY value is +15.70%. Year-to-date price return is +22.97%. Price CAGR uses adjusted close price history and excludes dividends.
Over the past 12 months, Price CAGR is 100.24%. The price CAGR (Compound Annual Growth Rate) shows how the company's stock price has grown over various time periods. This measures pure price appreciation without including dividends.
Palvella Therapeutics, Inc. (PVLA)
Price growth vs the same calendar quarter one year earlier, last 5 comparable quarters.
Quarter-end adjusted closing prices; the newest quarter may be quarter-to-date. Q4 2026 (2026-10-05): $132.16.
| Year | Start Price | End Price | Change | % Change |
|---|---|---|---|---|
| 2026 (YTD) | $104.67 | $132.16 | +$27.49 | +26.26% |
| 2025 | $12 | $104.67 | +$92.67 | +772.25% |
| Period | Period End | Value | QoQ Return | YoY Return |
|---|---|---|---|---|
| Q4 2026 (QTD) | 2026-10-05 | $132.16 | -4.2% | +26.3% |
| Q3 2026 | 2026-09-30 | $137.93 | -9.7% | +120.0% |
| Q2 2026 | 2026-06-30 | $152.82 | +22.6% | +578.0% |
| Q1 2026 | 2026-03-31 | $124.65 | +19.1% | +345.3% |
| Q4 2025 | 2025-12-31 | $104.67 | +67.0% | +772.3% |
| Q3 2025 | 2025-09-30 | $62.69 | +178.1% | N/A |
| Q2 2025 | 2025-06-30 | $22.54 | -19.5% | N/A |
| Q1 2025 | 2025-03-31 | $27.99 | +133.2% | N/A |
| Q4 2024 | 2024-12-31 | $12.00 | N/A | N/A |
Calendar returns: QoQ compares the prior calendar quarter; YoY compares the same calendar quarter a year earlier. The newest quarter is in progress (quarter-to-date).
